View Future GrowthBiomind Labs 과거 순이익 실적과거 기준 점검 0/6Biomind Labs의 연간 평균 수익은 92.3%였으며, Pharmaceuticals 산업의 수익은 연간 9.4% 증가했습니다.핵심 정보92.32%순이익 성장률99.10%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.공시 • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.공시 • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.공시 • Jul 19Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical TrialBiomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays.공시 • Sep 15Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical ApplicationsBiomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges.공시 • Aug 13Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent ApplicationBiomind Labs Inc. announced that it has filed a patent application in the United States Patent and Trademark Office (USPTO), its 4th patent application. The patent application filed in the USPTO relates to Biomind Labs’ proprietary technology on labeled DMT and an associated method for a personalized treatment of neurological and psychiatric disorders. The method monitors DMT levels in relevant body fluids facilitating the design of personalized treatments, regardless of metabolic, genetic, or environmental factors. Further, it is a novel method that allows the development of DMT based treatments available to the modern psychiatric clinical practice.매출 및 비용 세부 내역Biomind Labs가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:BMND.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-11031 Dec 250-11030 Sep 25000030 Jun 25000031 Mar 25000031 Dec 24000030 Sep 240-10030 Jun 240-10031 Mar 240-10031 Dec 230-11030 Sep 230-11130 Jun 230-22131 Mar 230-32131 Dec 220-32130 Sep 220-43030 Jun 220-54131 Mar 220-53131 Dec 210-43131 Mar 210-37136양질의 수익: BMND.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: BMND.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BMND.F는 수익성이 없지만 지난 5년 동안 연평균 92.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BMND.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BMND.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BMND.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/14 19:03종가2026/04/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biomind Labs Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.
공시 • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.
공시 • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.
공시 • Jul 19Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical TrialBiomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays.
공시 • Sep 15Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical ApplicationsBiomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges.
공시 • Aug 13Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent ApplicationBiomind Labs Inc. announced that it has filed a patent application in the United States Patent and Trademark Office (USPTO), its 4th patent application. The patent application filed in the USPTO relates to Biomind Labs’ proprietary technology on labeled DMT and an associated method for a personalized treatment of neurological and psychiatric disorders. The method monitors DMT levels in relevant body fluids facilitating the design of personalized treatments, regardless of metabolic, genetic, or environmental factors. Further, it is a novel method that allows the development of DMT based treatments available to the modern psychiatric clinical practice.